Attrition in the drug discovery process: Lessons to be learned from the safety pharmacology paradigm

Expert Review of Clinical Pharmacology

Volumn 5, Issue 3, 2012, Pages 237-240

  Curtis, Michael J ^a   Pugsley, Michael K ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

academia; cardiac toxicity; discovery pharmacology; drug attrition; drug development costs; intellectual property; safety pharmacology

Indexed keywords

PROPRANOLOL; SILDENAFIL; TERFENADINE;

ACADEMIC ADVISEMENT; ALLERGIC RHINITIS; ANGINA PECTORIS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FUNDING; HUMAN; NONHUMAN; PATENT; REVIEW; TORSADE DES POINTES;

DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS;

EID: 84861428777     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.22     Document Type: Review

References (6)

1. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin. Emerg. Drugs 15(3), 467-480 (2010).
2. Garnier JP. Rebuilding the R & D engine in big pharma. Harvard Bus. Rev. 86(5), 68-70, 72-76, 128 (2008).
3. Pugsley MK, Authier SA, Curtis MJ. Principles of safety pharmacology. Br. J. Pharmacol. 154(7), 1382-1399 (2008).
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151-185 (2003).
5. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8(12), 959-968 (2009).
6. Gelijns AC, Thier SO. Medical innovation and institutional interdependence: rethinking university- industry connections. JAMA 287(1), 72-77 (2002)